Wednesday, 4 September 2013

The Claimed Intermediate database by Tcipatent Ltd « New Drug Approvals

The Claimed Intermediate database by Tcipatent Ltd « New Drug Approvals:

'via Blog this'


Eddie Kehoe

Eddie Kehoe

Principal & Technical Director at Tcipatent Ltd
Hove, Brighton and Hove, United KingdomPharmaceuticalsThe Claimed Intermediate – a Structure Searchable Process Patent Database for Marketed Pharmaceutical Drugs (INNs).
Patent examining, searching, analysis and abstracting especially in the Chemical subject area.

          
The Claimed Intermediate is an online database
which covers Process Patents for Named Marketed Pharmaceutical Drugs – whether intermediates are claimed or not – for a low-cost subscription.
  • Structure Searchable
  • Includes INNs in at least one major Market
  • Includes Drug Synthesis often buried in a Plethora of Patents
  • Informs Pipeline decisions
  • Provides targeted Patent data in a Visual form
  • Informs Commercial Synthesis profitability
Click here for more information on our comprehensive solution
shared message from Eddie Kehoe
If anybody would like a trial of the database they could contact either myself eddie.kehoe@tcipatent.com, or my wife and fellow director, Pat Kehoe (pat.kehoe@tcipatent.com).
Here are temporary logons , please request trial
(deactivated automatically in five working days):
Link: Link: www.tcipatent.com/tcidb/
Structure Searchable Patent Database for Processes covering Named Marketed Pharmaceutical Drugs (INNs). The database is an ongoing Watching Service combined with a Backward Drug Service.
Eddie Kehoe
Principal & Technical Director
Tcipatent Ltd
www.tcipatent.com
info@tcipatent.om
tcipatent.com
Office: +44 (0)1273 736080
43 Farm Road, Hove, BN3 1FD, United Kingdom
Eddie Kehoe:
eddie.kehoe@tcipatent.com
Mobile – 07425629637
Skype – eddieskihoe
TWITTER-TCIPATENT
Pat Kehoe:
pat.kehoe@tcipatent.com
Mobile – 07585295531
Skype – patkehoe170348
Database Updates:
Recently Added Records
AliskirenAmbrisentan
AsenapineAtorvastatin
BosentanCabazitaxel
CefamandoleDasatinib
DesogestrelDexmedetomidine
DocetaxelDoripenem
DoxapramDuloxetine
EtonogestrelEtoricoxib
EtravirineFluvastatin
GefitinibIodixanol
IohexolIopamidol
LinagliptinMitiglinide
MontelukastMoxonidine
OseltamivirPaclitaxel
PerampanelPitavastatin
PravastatinPraziquantel
RitodrineRosuvastatin
SilodosinSitagliptin
TicagrelorUlipristal
Zidovudine
………..
photo

Coopers Cask - Pub in Hove BN3 1FB

Eddie is closeby

Sunday, 1 September 2013

Pharmaceutical R&D and its impact on global health


FACTS AND FIGURES 2012 - IFPMA

www.ifpma.org/.../IFPMA_-_Facts_And_Figures_2012_LowResSingleP...
Pharmaceutical R&D and its impact on global health . ...... An early-phase compound mayhave a promising outlook, but only preclinical and clinical trials will ... IFPMA (2012) Framework for action on NCDs – 2011–12 progress report. Geneva: ...

see pdf file at

NATURE’S VIAGRA-Health benefits of pomegranate by – By Dr. Janardhana V Hebbar, Ayurveda Expert « New Drug Approvals

NATURE’S VIAGRA-Health benefits of pomegranate by – By Dr. Janardhana V Hebbar, Ayurveda Expert « New Drug Approvals:

'via Blog this'

Drug firms and cancer………… Lucrative lifesavers « New Drug Approvals

Drug firms and cancer………… Lucrative lifesavers « New Drug Approvals:

'via Blog this'

Bayer’s Stivarga® (regorafenib) Tablets Approved in Europe « New Drug Approvals

Bayer’s Stivarga® (regorafenib) Tablets Approved in Europe « New Drug Approvals:

'via Blog this'

Otsuka Receives Complete Response Letter From U.S. Food And Drug Administration For Tolvaptan For Use In Patients With Autosomal Dominant Polycystic Kidney Disease « New Drug Approvals

Otsuka Receives Complete Response Letter From U.S. Food And Drug Administration For Tolvaptan For Use In Patients With Autosomal Dominant Polycystic Kidney Disease « New Drug Approvals:

'via Blog this'